All

Using Research Advocacy to Improve Outcomes

  Patient-driven care has become a recognized component of the approach that stakeholders use to advance therapies. The perspective and voice of the patient are widely seen as a valuable resource in identifying unmet needs and steering the direction of medical research. Individuals and entities engaged in this role are known as Research Advocates and…

Comparing ATRT, DIPG and ETMR Pediatric Brain Tumors

Pediatric brain tumors are the second most commonly diagnosed cancer in children, and the second leading cause of cancer death among children and infants. Despite significant improvements in outcomes for some pediatric cancers, when current treatments such as chemotherapy, surgery, or radiotherapy fail, there is still an unacceptably low chance of survival, in part because…

Grant Awarded for Research into Identifying and Treating Chemotherapy-Resistant Neuroblastoma

  Solving Kids’ Cancer with partners: Solving Kids’ Cancer UK, Solving Kids’ Cancer in New York, Joining Against Cancer in Kids (J-A-C-K), ZOE4LIFE, Merryn Lacy Trust, and the Oscar Knox Fund have awarded $650,000 to the Children’s Hospital of Philadelphia (CHOP) and collaborating institutions for research into identifying and treating neuroblastoma in newly diagnosed children…

International Collaboration Speeds Progress in Childhood Cancer Research

Despite major progress over the past several years, cancer is still the number one cause of death by disease in children past infancy in the developed world. In fact, of the approximately 360,000 children and adolescents across the globe diagnosed with cancer each year, 80% lack access to quality treatments and cures, highlighting the need to establish global networks to improve diagnoses and care. 

Therapeutic Antibody Treatment Options for Relapse/Refractory Neuroblastoma

Many clinical trials of anti-GD2 antibodies have been conducted, testing the antibodies as both standalone treatments or in combination with other drugs, such as immune-stimulating cytokines. Anti-GD2 antibodies have been approved for maintenance after reaching the first remission and for relapsed or refractory disease.

How a Child with Cancer Can Qualify for Social Security Benefits

There are a number of federal and state resources available to help families with limited income cover extra expenses while their child is sick. If your child qualifies for disability, he or she may be eligible for Supplemental Security Income (SSI) and Medicaid, even if already covered by another insurance. 

Sarcoma in Children

A sarcoma is a cancer that develops in bone or soft tissue. Soft tissue is the connective tissue between body parts and organs and can include muscles, tendons, fat, bone and cartilage, blood vessels, and lymph vessels. Sarcomas can be found anywhere in the body, but they are most often found in the arms, legs, chest, or abdomen. Pediatric sarcoma is sarcoma occurring in children, and accounts for approximately 15% of pediatric cancer cases, with 1,500 to 1,700 new cases diagnosed each year. 

Neuroblastoma in Children

Neuroblastoma is diagnosed in approximately 800 children in the United States each year. Ninety percent of cases occur in children under five years old, though the average age of diagnosis is between one and two years old. Still, because neuroblastomas form from fetal nerve cells, children as young as newborns can develop tumors, and neuroblastoma accounts for 50% of all cancer cases in infants.

Landmark Transatlantic Trial for Children with High-Risk Neuroblastoma Funded by Parent-Led Charities

In a landmark in pediatric oncology research, children with high-risk neuroblastoma across Europe and North America will be treated together for the first time, following the award of $1.4M to fund a new transatlantic clinical trial.

Podcast & Webinars

Sorry, we couldn't find any posts. Please try a different search.

Press Release

Clinical Trial Harnesses Power of Natural Killer Cells to Treat Neuroblastoma

Solving Kids’ Cancer, The Catherine Elizabeth Blair Memorial Foundation, and Wade’s Army awarded a $136,000 grant to support the novel immunotherapy clinical trial for childhood cancer.  Researchers will use a humanized monoclonal antibody linked to IL2, known as hu14.18-IL2, which specifically targets neuroblastoma tumor cells and binds to them, while the IL2 activates NK cells…

Transatlantic Clinical Trial For Children With Neuroblastoma is Open For Enrollment in the U.K. – Soon to Open in The U.S. and Germany

Solving Kids’ Cancer has partnered with Band of Parents, Joining Against Cancer in Kids (J-A-C-K), and Solving Kids’ Cancer Europe, to advance new treatment options for children with neuroblastoma with the launch of a transatlantic  Phase I clinical trial that is open for enrollment in the U.K. and will open soon in the US and Germany…

The Childhood Cancer STAR Act has been Signed!

The childhood cancer community and Solving Kids’ Cancer are grateful to our many champions in Congress, who successfully shepherded this bipartisan bill through both chambers. As a member of the Coalition Against Childhood Cancer (CAC2), we were proud to play a role in advancing and advocating for this legislation alongside CAC2’s advocacy partner coalition, the Alliance for Childhood Cancer, and the entire childhood cancer community.

Solving Kids’ Cancer 2018 Spring Celebration

On Wednesday, May 16th, Solving Kids’ Cancer (SKC), an NYC based nonprofit, held its annual Spring Celebration benefit gala at the Mandarin Oriental New York.  Mikhail “Doctor Mike” Varshavski served as the Master of Ceremonies of the event, which was hosted by Gabby & Gianpaolo, De Felice, Lindy Gad, Angelina Jolin, Jan Planit, Frederique van der Wal, and Bonnie Young and raised over $575,000 for pediatric cancer research.

Solving Kids’ Cancer to honor two industry leaders at 2018 Annual Spring Celebration Gala

On Wednesday, May 16th, Solving Kids’ Cancer (SKC) will hold its annual Spring Celebration Benefit Gala. This event, SKC’s signature research fundraiser, draws industry leaders from across the nation to celebrate distinguished individuals who have contributed to the advancement of pediatric cancer therapies. The 2018 honorees are Usman “Oz” Azam, MD, President and CEO of Tmunity Therapeutics and Thomas Gad, Founder and President of Y-mAbs Therapeutics.

Brain Tumor Clinical Trial Now Enrolling Children

A Phase 1 clinical trial leveraging the re-engineered poliovirus is now open for enrollment to children 12 years and older at the Preston Robert Tisch Brain Tumor Center, Duke University Medical Center. After years of following the progress of this promising therapy against adult glioblastoma and working with the research team on behalf of children, Solving Kids’ Cancer teamed up with The Andrew McDonough B+ Foundation to help move this forward in a trial for pediatric brain tumor patients.

Targeted Therapy for Children with ALK-Driven Neuroblastoma

Lorlatinib, an investigational drug candidate currently in late-stage clinical development for the treatment of lung cancer may also prove effective for the treatment of the pediatric cancer neuroblastoma. Solving Kids’ Cancer is leading an international effort of like-minded nonprofits to provide nearly $400,000 of collaborative funding for an innovative clinical trial to bring a potentially life-saving therapy to kids.

Advocacy in Action

Solving Kids’ Cancer was the first charity to ever go against the UK healthcare system without a pharmaceutical company involved. As a result, the National Institute for Health and Care Excellence (NICE) recently announced that it has upheld SKC’s appeal against the Institute’s decision not to recommend dinutuximab for treating high-risk neuroblastoma. 

Precision Medicine Advances for Children With Neuroblastoma

Solving Kids’ Cancer (SKC) together with Wade’s Army announce their joint financial support of this Phase 1 clinical trial to test the safety and efficacy of various investigational drugs that will leverage precision medicine for children with neuroblastoma. This Next Generation Personalized Neuroblastoma Therapy – also known as NEPENTHE (Greek for “medicine for sorrow”) – is the first precision medicine trial for children that will robustly analyze the genomics of their cancer and use combinations of investigational drugs to target specific mutations in their tumors.

News & Views

Using Research Advocacy to Improve Outcomes

  Patient-driven care has become a recognized component of the approach that stakeholders use to advance therapies. The perspective and voice of the patient are widely seen as a valuable resource in identifying unmet needs and steering the direction of medical research. Individuals and entities engaged in this role are known as Research Advocates and…

Comparing ATRT, DIPG and ETMR Pediatric Brain Tumors

Pediatric brain tumors are the second most commonly diagnosed cancer in children, and the second leading cause of cancer death among children and infants. Despite significant improvements in outcomes for some pediatric cancers, when current treatments such as chemotherapy, surgery, or radiotherapy fail, there is still an unacceptably low chance of survival, in part because…

Grant Awarded for Research into Identifying and Treating Chemotherapy-Resistant Neuroblastoma

  Solving Kids’ Cancer with partners: Solving Kids’ Cancer UK, Solving Kids’ Cancer in New York, Joining Against Cancer in Kids (J-A-C-K), ZOE4LIFE, Merryn Lacy Trust, and the Oscar Knox Fund have awarded $650,000 to the Children’s Hospital of Philadelphia (CHOP) and collaborating institutions for research into identifying and treating neuroblastoma in newly diagnosed children…

International Collaboration Speeds Progress in Childhood Cancer Research

Despite major progress over the past several years, cancer is still the number one cause of death by disease in children past infancy in the developed world. In fact, of the approximately 360,000 children and adolescents across the globe diagnosed with cancer each year, 80% lack access to quality treatments and cures, highlighting the need to establish global networks to improve diagnoses and care. 

Therapeutic Antibody Treatment Options for Relapse/Refractory Neuroblastoma

Many clinical trials of anti-GD2 antibodies have been conducted, testing the antibodies as both standalone treatments or in combination with other drugs, such as immune-stimulating cytokines. Anti-GD2 antibodies have been approved for maintenance after reaching the first remission and for relapsed or refractory disease.

How a Child with Cancer Can Qualify for Social Security Benefits

There are a number of federal and state resources available to help families with limited income cover extra expenses while their child is sick. If your child qualifies for disability, he or she may be eligible for Supplemental Security Income (SSI) and Medicaid, even if already covered by another insurance. 

Sarcoma in Children

A sarcoma is a cancer that develops in bone or soft tissue. Soft tissue is the connective tissue between body parts and organs and can include muscles, tendons, fat, bone and cartilage, blood vessels, and lymph vessels. Sarcomas can be found anywhere in the body, but they are most often found in the arms, legs, chest, or abdomen. Pediatric sarcoma is sarcoma occurring in children, and accounts for approximately 15% of pediatric cancer cases, with 1,500 to 1,700 new cases diagnosed each year. 

Neuroblastoma in Children

Neuroblastoma is diagnosed in approximately 800 children in the United States each year. Ninety percent of cases occur in children under five years old, though the average age of diagnosis is between one and two years old. Still, because neuroblastomas form from fetal nerve cells, children as young as newborns can develop tumors, and neuroblastoma accounts for 50% of all cancer cases in infants.

Landmark Transatlantic Trial for Children with High-Risk Neuroblastoma Funded by Parent-Led Charities

In a landmark in pediatric oncology research, children with high-risk neuroblastoma across Europe and North America will be treated together for the first time, following the award of $1.4M to fund a new transatlantic clinical trial.

Videos

Give Hope & Love

When the world entered the COVID-19 pandemic, all we needed was a little Hope & Love. We asked all of our young ambassadors to share their messages of hope to the world. A big thank you to all of the frontline workers who risked their lives during the world pandemic. From all of us at Solving Kids’ Cancer

Lace Up For Kids 2019: Childhood Cancer Awareness Month

The “Lace Up For Kids” campaign connected childhood cancer supporters and advocates both nationally and internationally. For the month of September, thousands of gold shoelaces were shipped and worn to help raise awareness for Childhood Cancer Awareness Month. Take a look at some of the people who participated – you may even recognize some influencers and celebrities!

2018 Spring Celebration

On Wednesday, May 16th, Solving Kids’ Cancer (SKC), an NYC based nonprofit, held its annual Spring Celebration benefit gala at the Mandarin Oriental New York. Mikhail “Doctor Mike” Varshavski served as the Master of Ceremonies of the event, which was hosted by Gabby & Gianpaolo, De Felice, Lindy Gad, Angelina Jolin, Jan Planit, Frederique van der Wal, and Bonnie Young and raised over $575,000 for pediatric cancer research.

2016: A Year at a Glance for SKC

Join us and watch as we recap all of the milestones & events Solving Kids’ Cancer experienced during 2016. From our 6th Annual Spring Celebration to SKC appealing NICE’s decision in the UK – none of these accomplishments could have been possible without the help of our supporters. Thank you & Happy New Year!

Meet the Inspiring Kids of Runway Heroes 2016

Runway Heroes is a fun-filled fashion show featuring childhood cancer fighters and survivors ranging in age from 3 to 13 years of age. The runway is presented by Bloomingdale’s at its flagship Manhattan store, and benefits Solving Kids’ Cancer and the Ronan Thompson Foundation, two like-minded nonprofits that collaborate on funding innovative childhood cancer research. In high fashion and chic style, these runway stars shine with a sense of pride and accomplishment as they strut their stuff in trend-setting outfits donated by Bloomingdale’s.

Highlights from the 2016 Spring Celebration Gala

On Monday, May 16th, Solving Kids Cancer held its 7th Annual Spring Celebration honoring Gary Armen, Ph.D., Chairman and CEO of Agenus, who received the Wings of Hope Award. Good Morning America News Anchor, Amy Robach, served as the Mistress of Ceremonies. The event, which raised over $750,000, was hosted by Donna Karan, Gabby Karan De Felice, Bonnie Young, Jan Planit, and Latham Thomas. The 2016 benefit celebrated the renewal of spring and children everywhere. The evening included an award presentation of the Gold Star Award from New York Giant’s athletes, Victor Cruz and Jason Pierre-Paul, to 10 deserving heroes.

Accelerating Research For Pediatric Brain Tumors

Meet Dr. Mark Souweidane from Weill Cornell Medical Center and listen in as we interview him and two childhood cancer families about his clinical trial that Solving Kids’ Cancer funded for children with brain tumors.

2015: A Year at a Glance for SKC

2015 proved to be a critical year for Solving Kids’ Cancer. Watch as we reflect on all of this year’s accomplishments including the opportunity to ring the closing Nasdaq bell to our exclusive interview with WCBS Radio and Newsweek. Thank you all for a remarkable year!

Understanding the Landscape, Strengthening the Science, Curing and Caring for the Child

Solving Kids’ Cancer’s approach is to understand the research landscape, strengthen the science, cure, and care for the child. The GD2 T Cell Therapy trial at Texas Children’s Hospital is helping children with neuroblastoma like Kyra Kardong – listen to her story.